{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:06:07Z","timestamp":1763827567824,"version":"3.45.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03111-7","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:09:20Z","timestamp":1762362560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defeating miR-181a-3p may potentiate the effect of paclitaxel on G2\/M arrest in breast cancer stem cells"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-4175","authenticated-orcid":false,"given":"Aycan","family":"Asik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-7455","authenticated-orcid":false,"given":"Bakiye","family":"Goker Bagca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-4644","authenticated-orcid":false,"given":"Neslihan Pinar","family":"Ozates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-8921","authenticated-orcid":false,"given":"Roya","family":"Gasimli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-4520","authenticated-orcid":false,"given":"Cigir","family":"Biray Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-3237","authenticated-orcid":false,"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"3111_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3111_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bpobgyn.2022.02.004","volume":"82","author":"NM Grogan Fleege","year":"2022","unstructured":"Grogan Fleege NM, Cobain EF. Breast cancer management in 2021: a primer for the obstetrics and gynecology. Best Pract Res Clin Obstet Gynaecol. 2022;82:30\u201345. https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.02.004.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"3111_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2","volume":"6","author":"A Marra","year":"2020","unstructured":"Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54. https:\/\/doi.org\/10.1038\/s41523-020-00197-2.","journal-title":"NPJ Breast Cancer"},{"key":"3111_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2014.06.022","volume":"353","author":"F Ma","year":"2014","unstructured":"Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, et al. Enriched CD44+\/CD24\u2009\u2013\u2009population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353:153\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2014.06.022.","journal-title":"Cancer Lett"},{"key":"3111_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cai2.46","volume":"2","author":"J Zhai","year":"2023","unstructured":"Zhai J, Wu Y, Ma F, Kaklamani V, Xu B. Advances in medical treatment of breast cancer in 2022. Cancer Innov. 2023;2:1\u201317. https:\/\/doi.org\/10.1002\/cai2.46.","journal-title":"Cancer Innov"},{"key":"3111_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41632-0","volume":"9","author":"N Gupta","year":"2019","unstructured":"Gupta N, Gupta P, Srivastava SK. Penfluridol overcomes Paclitaxel resistance in metastatic breast cancer. Sci Rep. 2019;9:5066. https:\/\/doi.org\/10.1038\/s41598-019-41632-0.","journal-title":"Sci Rep"},{"key":"3111_CR7","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.13168","volume":"23","author":"J Esparza-l\u00f3pez","year":"2021","unstructured":"Esparza-l\u00f3pez J, Longoria O, De La Cruz-escobar E, Garibay-d\u00edaz J, Le\u00f3n-rodr\u00edguez E, Ibarra-s\u00e1nchez M. Paclitaxel resistance is mediated by NF-\u03baB on mesenchymal primary breast cancer cells. Oncol Lett. 2021;23:50. https:\/\/doi.org\/10.3892\/ol.2021.13168.","journal-title":"Oncol Lett"},{"key":"3111_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02503-9","volume":"11","author":"TM Khing","year":"2021","unstructured":"Khing TM, Choi WS, Kim DM, Po WW, Thein W, Shin CY, et al. The effect of Paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells. Sci Rep. 2021;11:23490. https:\/\/doi.org\/10.1038\/s41598-021-02503-9.","journal-title":"Sci Rep"},{"key":"3111_CR9","doi-asserted-by":"publisher","first-page":"19807","DOI":"10.1002\/cam4.6552","volume":"12","author":"H Xu","year":"2023","unstructured":"Xu H, Li L, Dong B, Lu J, Zhou K, Yin X, et al. TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2-mediated glycolysis. Cancer Med. 2023;12:19807\u201320. https:\/\/doi.org\/10.1002\/cam4.6552.","journal-title":"Cancer Med"},{"key":"3111_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/137414","volume":"2013","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer. 2013;2013:1\u201315. https:\/\/doi.org\/10.1155\/2013\/137414.","journal-title":"Int J Breast Cancer"},{"key":"3111_CR11","doi-asserted-by":"publisher","DOI":"10.4103\/ctm.ctm_69_16","volume":"3","author":"W Zhao","year":"2017","unstructured":"Zhao W, Li Y, Zhang X. Stemness-related markers in cancer. Cancer Transl Med. 2017;3:87. https:\/\/doi.org\/10.4103\/ctm.ctm_69_16.","journal-title":"Cancer Transl Med"},{"key":"3111_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrg3722","volume":"15","author":"KV Morris","year":"2014","unstructured":"Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014;15:423\u201337. https:\/\/doi.org\/10.1038\/nrg3722.","journal-title":"Nat Rev Genet"},{"key":"3111_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0185-1","volume":"15","author":"KB Reddy","year":"2015","unstructured":"Reddy KB. Microrna (miRNA) in cancer. Cancer Cell Int. 2015;15:38. https:\/\/doi.org\/10.1186\/s12935-015-0185-1.","journal-title":"Cancer Cell Int"},{"key":"3111_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.apsb.2016.09.002","volume":"7","author":"X An","year":"2017","unstructured":"An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by MicroRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7:38\u201351. https:\/\/doi.org\/10.1016\/j.apsb.2016.09.002.","journal-title":"Acta Pharm Sin B"},{"key":"3111_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233962","volume":"16","author":"TH Vo","year":"2024","unstructured":"Vo TH, McNeela EA, O\u2019Donovan O, Rani S, Mehta JP. Mechanism of miRNAs and miRNA-mRNA regulatory networks in modulating drug resistance in HER2-positive breast cancer: an integrative bioinformatics approach. Cancers (Basel). 2024;16:3962. https:\/\/doi.org\/10.3390\/cancers16233962.","journal-title":"Cancers (Basel)"},{"key":"3111_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna9020027","volume":"9","author":"E Bayraktar","year":"2023","unstructured":"Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Non-coding RNA. 2023;9:27. https:\/\/doi.org\/10.3390\/ncrna9020027.","journal-title":"Non-coding RNA"},{"key":"3111_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.phrs.2015.04.015","volume":"97","author":"PJ Kaboli","year":"2015","unstructured":"Kaboli PJ, Rahmat A, Ismail P, Ling K-H. MicroRNA-based therapy and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 2015;97:104\u201321. https:\/\/doi.org\/10.1016\/j.phrs.2015.04.015.","journal-title":"Pharmacol Res"},{"key":"3111_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01151-y","volume":"13","author":"MA Bustos","year":"2023","unstructured":"Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, et al. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell Biosci. 2023;13:200. https:\/\/doi.org\/10.1186\/s13578-023-01151-y.","journal-title":"Cell Biosci"},{"key":"3111_CR19","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.2147\/OTT.S228800","volume":"12","author":"W Huang","year":"2019","unstructured":"Huang W, Liu J, Hu S, Shi G, Yong Z, Li J, et al. Mir-181a upregulation promotes radioresistance of nasopharyngeal carcinoma by targeting RKIP. Onco Targets Ther. 2019;12:10873\u201384. https:\/\/doi.org\/10.2147\/OTT.S228800.","journal-title":"Onco Targets Ther"},{"key":"3111_CR20","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141","volume":"47","author":"A Kozomara","year":"2019","unstructured":"Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: from MicroRNA sequences to function. Nucleic Acids Res. 2019;47:D155\u201362. https:\/\/doi.org\/10.1093\/nar\/gky1141.","journal-title":"Nucleic Acids Res"},{"key":"3111_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/21655979.2021.2006974","volume":"13","author":"Z Zhai","year":"2022","unstructured":"Zhai Z, Mu T, Zhao L, Li Y, Zhu D, Pan Y. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN\/AKT pathway. Bioengineered. 2022;13:83\u201395. https:\/\/doi.org\/10.1080\/21655979.2021.2006974.","journal-title":"Bioengineered"},{"key":"3111_CR22","doi-asserted-by":"publisher","first-page":"D1055","DOI":"10.1093\/nar\/gkab733","volume":"50","author":"I Kavakiotis","year":"2022","unstructured":"Kavakiotis I, Alexiou A, Tastsoglou S, Vlachos IS, Hatzigeorgiou AG. DIANA-miTED: a MicroRNA tissue expression database. Nucleic Acids Res. 2022;50:D1055\u201361. https:\/\/doi.org\/10.1093\/nar\/gkab733.","journal-title":"Nucleic Acids Res"},{"key":"3111_CR23","doi-asserted-by":"publisher","unstructured":"McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM et al. The biochemical basis of microRNA targeting efficacy. Sci. (1979). 2019;366. https:\/\/doi.org\/10.1126\/science.aav1741","DOI":"10.1126\/science.aav1741"},{"key":"3111_CR24","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u201346. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","journal-title":"Nucleic Acids Res"},{"key":"3111_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017. https:\/\/doi.org\/10.1126\/science.aan2507.","journal-title":"Science"},{"key":"3111_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0039-y","volume":"9","author":"F Lucantoni","year":"2018","unstructured":"Lucantoni F, Lindner AU, O\u2019Donovan N, D\u00fcssmann H, Prehn JHM. Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells. Cell Death Dis. 2018;9:42. https:\/\/doi.org\/10.1038\/s41419-017-0039-y.","journal-title":"Cell Death Dis"},{"key":"3111_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70803","author":"R Raman","year":"2025","unstructured":"Raman R, Debata S, Govindarajan T, Kumar P. Targeting triple-negative breast cancer: resistance mechanisms and therapeutic advancements. Cancer Med. 2025. https:\/\/doi.org\/10.1002\/cam4.70803.","journal-title":"Cancer Med"},{"key":"3111_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14364-2","volume":"7","author":"W Li","year":"2017","unstructured":"Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44\/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7:13856. https:\/\/doi.org\/10.1038\/s41598-017-14364-2.","journal-title":"Sci Rep"},{"key":"3111_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07273","volume":"7","author":"J Enciso-Benavides","year":"2021","unstructured":"Enciso-Benavides J, Alfaro L, Casta\u00f1eda-Altamirano C, Rojas N, Gonz\u00e1lez-Cabeza J, Enciso N, et al. Biological characteristics of a sub-population of cancer stem cells from two triple-negative breast tumour cell lines. Heliyon. 2021;7:e07273. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07273.","journal-title":"Heliyon"},{"key":"3111_CR30","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1080\/09553002.2023.2232019","volume":"99","author":"R Gasimli","year":"2023","unstructured":"Gasimli R, Kayabasi C, Ozmen Yelken B, Asik A, Sogutlu F, Celebi C, et al. The effects of PKI-402 on breast tumor models\u2019 radiosensitivity via dual inhibition of PI3K\/mTOR. Int J Radiat Biol. 2023;99:1961\u201370. https:\/\/doi.org\/10.1080\/09553002.2023.2232019.","journal-title":"Int J Radiat Biol"},{"key":"3111_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5556","volume":"63","author":"J Li","year":"2023","unstructured":"Li J, Shen J, Zhao Y, Du F, Li M, Xu X, et al. Role of miR-181a-5p in cancer (Review). Int J Oncol. 2023;63:108. https:\/\/doi.org\/10.3892\/ijo.2023.5556.","journal-title":"Int J Oncol"},{"key":"3111_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09272-4","volume":"51","author":"H Fouladi","year":"2024","unstructured":"Fouladi H, Ebrahimi A, Derakhshan SM, Khaniani MS. Over-expression of mir-181a-3p in serum of breast cancer patients as diagnostic biomarker. Mol Biol Rep. 2024;51:372. https:\/\/doi.org\/10.1007\/s11033-024-09272-4.","journal-title":"Mol Biol Rep"},{"key":"3111_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154702","volume":"249","author":"A Ebrahimi","year":"2023","unstructured":"Ebrahimi A, Bakhshaei Shahrebabaki P, Fouladi H, Mansoori Derakhshan S. The impact of MicroRNAs on the resistance of breast cancer subtypes to chemotherapy. Pathol Res Pract. 2023;249:154702. https:\/\/doi.org\/10.1016\/j.prp.2023.154702.","journal-title":"Pathol Res Pract"},{"key":"3111_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706095","author":"B Liu","year":"2022","unstructured":"Liu B, Hu J, Zhao H, Zhao L, Pan S. Microrna-155-5p contributes to 5-fluorouracil resistance through down-regulating TP53INP1 in oral squamous cell carcinoma. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2021.706095.","journal-title":"Front Oncol"},{"key":"3111_CR35","doi-asserted-by":"publisher","first-page":"746","DOI":"10.4149\/neo_2018_181207N930","volume":"66","author":"L Tao","year":"2019","unstructured":"Tao L, Wu YQ, Zhang SP. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma. 2019;66:746\u201355. https:\/\/doi.org\/10.4149\/neo_2018_181207N930.","journal-title":"Neoplasma"},{"key":"3111_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14493","author":"L Wang","year":"2024","unstructured":"Wang L, Sun Y, Liu H, Yang X, Wen Z, Tian X. \u03b2-Sitosterol attenuates anlotinib resistance in non\u2010small cell lung cancer cells by inhibiting miR\u2010181a\u20103p\/ SHQ1\u2009signaling. Chem Biol Drug Des. 2024. https:\/\/doi.org\/10.1111\/cbdd.14493.","journal-title":"Chem Biol Drug Des"},{"key":"3111_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/0115734099252873231117072107","volume":"21","author":"L Wang","year":"2025","unstructured":"Wang L, Sun T, Yang X, Wen Z, Sun Y, Liu H. Astragaloside IV overcomes anlotinib resistance in non-small cell lung cancer through miR-181a-3p\/UPR-ERAD axis. Curr Comput Aided Drug Des. 2025;21:441\u201351. https:\/\/doi.org\/10.2174\/0115734099252873231117072107.","journal-title":"Curr Comput Aided Drug Des"},{"key":"3111_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s41236-020-0010-1","volume":"4","author":"Y Shen","year":"2020","unstructured":"Shen Y, Schmidt BUS, Kubitschke H, Morawetz EW, Wolf B, K\u00e4s JA, et al. Detecting heterogeneity in and between breast cancer cell lines. Cancer Converg. 2020;4:1. https:\/\/doi.org\/10.1186\/s41236-020-0010-1.","journal-title":"Cancer Converg"},{"key":"3111_CR39","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrm2434","volume":"9","author":"Y-LP Ow","year":"2008","unstructured":"Ow Y-LP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol. 2008;9:532\u201342. https:\/\/doi.org\/10.1038\/nrm2434.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3111_CR40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/cbdd.14309","volume":"102","author":"L Ying","year":"2023","unstructured":"Ying L, Hao M, Zhang Z, Guo R, Liang Y, Yu C, et al. Medicarpin suppresses proliferation and triggeres apoptosis by upregulation of <\u2009scp\u2009>\u2009BID, <scp\u2009>\u2009BAX, <scp\u2009>\u2009CASP3, <scp\u2009>\u2009CASP8, and <\u2009scp\u2009>\u2009CYCS in glioblastoma<\/scp\u2009><\/scp\u2009><\/scp\u2009>. Chem Biol Drug Des. 2023;102:1097\u2013109. https:\/\/doi.org\/10.1111\/cbdd.14309.","journal-title":"Chem Biol Drug Des"},{"key":"3111_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30603-6","volume":"8","author":"D Stehle","year":"2018","unstructured":"Stehle D, Grimm M, Einsele-Scholz S, Ladwig F, Joh\u00e4nning J, Fischer G, et al. Contribution of BH3-domain and transmembrane-domain to the activity and interaction of the pore-forming Bcl-2 proteins Bok, Bak, and Bax. Sci Rep. 2018;8:12434. https:\/\/doi.org\/10.1038\/s41598-018-30603-6.","journal-title":"Sci Rep"},{"key":"3111_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138955","volume":"10","author":"Y Luo","year":"2015","unstructured":"Luo Y, Wang X, Wang H, Xu Y, Wen Q, Fan S, et al. High bak expression is associated with a favorable prognosis in breast cancer and sensitizes breast cancer cells to Paclitaxel. PLoS One. 2015;10:e0138955. https:\/\/doi.org\/10.1371\/journal.pone.0138955.","journal-title":"PLoS One"},{"key":"3111_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051110","volume":"9","author":"P Duda","year":"2020","unstructured":"Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, et al. Targeting GSK3 and associated signaling pathways involved in cancer. Cells. 2020;9:1110. https:\/\/doi.org\/10.3390\/cells9051110.","journal-title":"Cells"},{"key":"3111_CR44","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1535-7163.MCT-19-0261","volume":"18","author":"L Liu","year":"2019","unstructured":"Liu L, Meng T, Zheng X, Liu Y, Hao R, Yan Y, et al. Transgelin 2 promotes Paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K\/Akt\/GSK-3\u03b2 pathway. Mol Cancer Ther. 2019;18:2457\u201368. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0261.","journal-title":"Mol Cancer Ther"},{"key":"3111_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/mc.22321","volume":"55","author":"L Zhao","year":"2016","unstructured":"Zhao L, Miao H-C, Li W-J, Sun Y, Huang S, Li Z-Y, et al. LW-213 induces G2\/M cell cycle arrest through AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway in human breast cancer cells. Mol Carcinog. 2016;55:778\u201392. https:\/\/doi.org\/10.1002\/mc.22321.","journal-title":"Mol Carcinog"},{"key":"3111_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040857","volume":"9","author":"M Hammouda","year":"2020","unstructured":"Hammouda M, Ford A, Liu Y, Zhang J. The JNK signaling pathway in inflammatory skin disorders and cancer. Cells. 2020;9:857. https:\/\/doi.org\/10.3390\/cells9040857.","journal-title":"Cells"},{"key":"3111_CR47","first-page":"2183","volume":"11","author":"C-L Zhai","year":"2018","unstructured":"Zhai C-L, Tang G-M, Qian G, Han B-J, Hu H-L, Wang S-J, et al. miR-190 protects cardiomyocytes from apoptosis induced by H2O2 through targeting MAPK8 and regulating MAPK8\/ERK signal pathway. Int J Clin Exp Pathol. 2018;11:2183\u201392.","journal-title":"Int J Clin Exp Pathol"},{"key":"3111_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057329","volume":"8","author":"N Tiwari","year":"2013","unstructured":"Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegen E, et al. Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8). PLoS One. 2013;8:e57329. https:\/\/doi.org\/10.1371\/journal.pone.0057329.","journal-title":"PLoS One"},{"issue":"4","key":"3111_CR49","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1002\/jcp.27196","volume":"234","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Dai Y, Liu W, Wang N, Cai Y, Wang S, et al. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1\u2010targeting oxidant damage. J Cell Physiol. 2019;234(4):4277\u201390. https:\/\/doi.org\/10.1002\/jcp.27196.","journal-title":"J Cell Physiol"},{"key":"3111_CR50","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-06-2644","volume":"67","author":"GW Small","year":"2007","unstructured":"Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007;67:4459\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2644.","journal-title":"Cancer Res"},{"key":"3111_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914882","volume":"24","author":"H Werner","year":"2023","unstructured":"Werner H. The IGF1 signaling pathway: from basic concepts to therapeutic opportunities. Int J Mol Sci. 2023;24:14882. https:\/\/doi.org\/10.3390\/ijms241914882.","journal-title":"Int J Mol Sci"},{"key":"3111_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111759","volume":"41","author":"J-S Lee","year":"2022","unstructured":"Lee J-S, Lero MW, Mercado-Matos J, Zhu S, Jo M, Tocheny CE, et al. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2\/PI3K-mediated regulation of MYC. Cell Rep. 2022;41:111759. https:\/\/doi.org\/10.1016\/j.celrep.2022.111759.","journal-title":"Cell Rep"},{"key":"3111_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3724\/abbs.2022008","volume":"54","author":"P Liu","year":"2022","unstructured":"Liu P, Sun Y, Liu S, Niu J, Liu X, Chu Q. SY-707, an ALK\/FAK\/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells. Acta Biochim Biophys Sin. 2022;54:252\u201360. https:\/\/doi.org\/10.3724\/abbs.2022008.","journal-title":"Acta Biochim Biophys Sin"},{"key":"3111_CR54","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.66","author":"KKW To","year":"2024","unstructured":"To KKW, Zhang H, Cho WC. Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy. Cancer Drug Resist. 2024. https:\/\/doi.org\/10.20517\/cdr.2024.66.","journal-title":"Cancer Drug Resist"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03111-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:02:37Z","timestamp":1763827357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03111-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":54,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3111"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03111-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"As this research utilized commercially available cell lines, no ethical approval was necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"538"}}